仍志集團控股(08079.HK)終止供股及包銷協議
格隆匯1月16日丨仍志集團控股(08079.HK)公吿,內容有關按全面包銷基準及每股供股股份0.045港元認購價進行供股,基準為於記錄日期每持有一(1)股現有股份獲發三(3)股供股股份。董事會宣佈,鑑於當前市況及投資者氛圍,公司與包銷商一致同意終止包銷協議,即時生效。包銷協議因此終止且不再具有進一步效力,且任何一方均無須就包銷協議向另一方承擔任何責任。於公吿日期,公司概無根據供股發行任何證券。供股將不會進行且供股將失效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.